Surrozen Wins FDA Clearance to Test SZN-8141 for Eye Disease
Surrozen received FDA clearance for an IND application to begin clinical trials of SZN-8141 targeting diabetic macular edema.
Surrozen has secured U.S. Food and Drug Administration clearance of an Investigational New Drug application for SZN-8141, its experimental therapy aimed at treating diabetic macular edema, a leading cause of vision loss among people with diabetes. The IND clearance marks a regulatory milestone that allows the company to move forward with human clinical trials in the United States.
Diabetic macular edema occurs when fluid accumulates in the macula — the central portion of the retina responsible for sharp, detailed vision — as a complication of diabetes-related damage to blood vessels in the eye. The condition affects millions of Americans and represents a significant unmet medical need despite existing treatment options.
Read more Biogen's Litifilimab Shows Durable CLE Benefits at 52 Weeks →
SZN-8141 is Surrozen's candidate designed to address this condition, though the precise mechanism and preclinical data supporting the drug's advancement were not detailed in the announcement. FDA clearance of an IND application means regulators found no grounds to place the proposed trial on clinical hold, allowing patient enrollment and dosing to proceed under the submitted protocol.
The development positions Surrozen among the companies pursuing novel approaches to retinal disease, a therapeutic area that has attracted considerable pharmaceutical interest given the growing global prevalence of diabetes and its ocular complications. The company's next steps would likely involve initiating Phase 1 or early-phase clinical studies to evaluate safety, tolerability, and early efficacy signals in patients.
Continue reading at GlobeNewswire - Industry News on Financial Services.
